Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, June 01 2022 - 18:15
PMB Announces EIT Health Supported FLASHKNiFE Consortium Towards the Clinical Application of FLASH Radiation Therapy
PEYNIER, France, June 1, 2022 /PRNewswire-AsiaNet/ --

PMB announces the launch of the FLASHKNiFE Consortium, supported by the 
European Institute of Innovation & Technology for Health (EIT Health). This 
European public-private partnership aims at advancing radiation therapy by 
introducing a new radiotherapy device into clinical practice.

More than 10 million patients receive radiation therapy each year worldwide, 
making it an essential tool for cancer treatment, along with surgery and 
chemotherapy. Moreover, 30% to 40% of treated patients are resistant to 
radiotherapy. Radiation-induced side effects severely limit the radiation dose 
given to the tumor. If toxicity could be reduced, a greater dose of radiation 
could be given, providing a more efficient and better tolerated outcome in 
cancer treatment.

The FLASHKNiFE Consortium aims to address this challenge by using FLASH 
radiation therapy, a recently discovered method of administering radiotherapy. 
Given in a single, very short treatment session, FLASH radiotherapy has been 
shown to cause less side effects than conventional radiotherapy in several 
preclinical and clinical studies.

The Consortium brings together high-profile institutions across Europe who will 
be working over the next three years to achieve this goal: PMB, Alcen, Institut 
Gustave Roussy, Centro Hospitalar Lisboa Norte, Universitatsklinikum Erlangen 
and ProductLife Group. With a total budget of Euro 8.2 million, FLASHKNiFE is 
co-funded by the EIT Health (Euro 2.5M) and the partners.

To advance the clinical application of FLASH radiotherapy, the FLASHKNiFE 
Consortium as well as our additional clinical partner CHUV, will conduct a 
multi-centric clinical investigation on skin cancer, starting in 2023.

Prof. Eric Deutsch, Head of Gustave Roussy Radiotherapy Department, says: "the 
decision to embark on this very exciting EIT Health project was made because it 
brought together a biological innovation, the FLASH concept, a technology 
innovation, FLASHKNiFE, and the ability to turn these innovations into reality 
for the patient."

About PMB: 
PMB is an innovative company specialized in the design and manufacture of 
complex mechanical assemblies for the industries of Defense, Medical and 
Research. Since the late 2000s, the company has developed complex systems 
integrating particle accelerators for nuclear medicine, non-destructive 
testing, and a FLASH radiotherapy system. PMB is a subsidiary of Alcen, an 
industrial diversified French group with a strong focus on innovation advancing 
societal challenges.

For more information visit:     
Press Information:
Fatine Slaoui 
+33 4 42 53 13 13
Home page | FLASHKNiFE project [ ]

Video -
Photo -
Photo -
Logo -

Source: PMB-Alcen and FLASHKNiFE Consortium